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Summary
Background.— Echocardiography is recommended for all patients with a clinical diagnosis of
heart failure (HF). Management of HF in daily practice differs from guidelines.
Aim.— To evaluate the prognostic impact of echocardiography in patients hospitalized for a
ﬁrst episode of HF.
Methods.— Consecutive patients (n = 799) hospitalized for a ﬁrst episode of HF were prospec-
tively enrolled during 2000. Propensity scores and multivariable analyses were used to reduce
the imbalance in baseline covariates between the Echo and No-Echo groups.
Results.— During hospitalization, echocardiography was not performed in 151 patients (19%).
Patients in the No-Echo group were older, more likely to be female, less frequently admitted to
cardiology departments, and had lower rates of life-saving drugs prescribed at discharge. After
adjustment for covariates of prognostic importance, use of echocardiography was associated
with lower relative risk of three-year overall mortality (hazard ratio [HR] 0.61, 95% conﬁdence
interval [CI] 0.48—0.78, p < 0.001) and cardiovascular mortality (HR 0.52, 95% CI 0.39—0.70,
p < 0.001). The three-year relative survival of the Echo group (observed/expected survival) was
higher than that of the No-Echo group. Using propensity scores, the performance of echocar-
diography during hospitalization remained related to reduced three-year overall mortality (HR
0.55, 95% CI 0.39—0.79, p = 0.001) and cardiovascular mortality (HR 0.59, 95% CI 0.37—0.95,
p = 0.03).
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Conclusion.— L’échocardiographie n’est pas réalisée dans environ 20% des hospitalisations pour
première poussée d’IC, en particulier chez les sujets âgés. La réalisation d’une échocardiogra-
men
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bbreviations
CE Angiotensin-converting enzyme
I Conﬁdence interval
OPD Chronic obstructive pulmonary disease
cho Echocardiography
F Heart failure
R Hazard ratio
YHA New York Heart Association
ackground
he incidence and prevalence of heart failure (HF) have now
eached epidemic proportions. As patients with this condi-
ion face a high risk of hospitalization and mortality, HF has
ecome an increasingly important economic issue. European
nd American guidelines support the major role of echocar-
iography in the initial evaluation of patients with HF [1,2].
chocardiography is a cost-effective modality, suitable for
valuating morphological and functional cardiac abnormal-
ties in HF. It identiﬁes the underlying causes and helps to
mprove the management of patients with HF primarily by
ssessing response to therapy.
Signiﬁcant differences exist between clinical guidelines
n HF and routine clinical practice. In the EuroHeart Failure
p
p
t
wt médical plus intensif et à un meilleur pronostic.
rights reserved.
urvey that included patients with suspected or conﬁrmed
F, echocardiography was performed in 66% of cases [3].
o our knowledge, only one study, which was retrospective
n design, has reported the impact of echocardiography on
ortality in patients hospitalized for HF [4]. The aims of
he current prospective study, which included consecutive
atients admitted to hospital for a ﬁrst episode of HF, were:
to analyse the clinical features and treatment of patients
in whom echocardiography was not performed during the
initial hospitalization, and;
to determine whether the use of echocardiography is asso-
ciated with better clinical outcomes.
ethods
tudy population and data collection
he Somme is a French department with a population of
55,551 inhabitants according to the 1999 census. It has a
otal of 11 healthcare institutions managing patients with
F: one university hospital, seven general hospitals, twoC. Tribouilloy et al.
Conclusion.— Echocardiography is still underused in elderly patients with HF. Use of echocardio-
graphy appears to be associated with more intensive medical therapy and improved outcome.
© 2008 Elsevier Masson SAS. All rights reserved.
Résumé
Introduction.— La pratique d’une échocardiographie est recommandée chez les patients ayant
un diagnostic clinique d’insufﬁsance cardiaque (IC).
Objectifs.— Évaluer l’impact pronostique de l’échocardiographie effectuée pendant
l’hospitalisation sur l’évolution à long terme des patients admis pour une première poussée
d’IC.
Méthodes.— Sept cent quatre-vingt-dix-neuf patients consécutifs hospitalisés pour une pre-
mière poussée d’IC pendant l’année 2000 ont été prospectivement inclus. Les patients ont été
divisés en deux groupes (groupe I : écho ; groupe II : pas d’écho) selon qu’une échocardiogra-
phie ait été réalisée ou non pendant l’hospitalisation. Dans le but de réduire le déséquilibre
des variables de base entre les deux groupes, un appariement selon la méthode du propensity
analysis et une analyse multivariée ont été pratiqués.
Résultats.— L’échocardiographie n’a pas été réalisée pendant l’hospitalisation dans 19 % des cas
(groupe II ; n = 151). Les patients du groupe II étaient plus âgés, plus souvent de sexe féminin, et
moins souvent hospitalisés en cardiologie. Les médicaments qui inﬂuencent de manière favor-
able la survie dans l’IC étaient moins prescrits dans le groupe II. Après l’ajustement aux facteurs
pronostiques classiques, la pratique d’une échocardiographie était associée à une réduction sig-
niﬁcative de la mortalité totale (hazard ratio [HR] 0,61 ; 95 %CI 0,48—0,78 ; p < 0,001) et de la
mortalité cardiovasculaire (HR 0,52 ; 95 %CI 0,39—0,70 ; p < 0,001) à trois ans. La survie relative
à trois ans du groupe I (survie observée/survie théorique) était supérieure à celle du groupe II.
Après appariement, la réalisation d’une échocardiographie pendant l’hospitalisation demeurait
associée à une réduction de la mortalité totale (HR 0,55 ; 95 %CI 0,39—0,79 ; p = 0,001) et de la
mortalité cardiovasculaire (HR 0,59 ; 95 %CI 0,37—0,95 ; p = 0,03).rivate clinics, and one medium-to-long-stay unit. General
ractitioners, cardiologists and internal physicians in all of
hese centres agreed to participate in this study.
Consecutive patients aged greater or equal to 20 years
ho were hospitalized in 2000 for a ﬁrst episode of HF in
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these institutions were enrolled prospectively. Patients liv-
ing outside the Somme department, patients hospitalized for
subsequent episodes of HF, and patients with severe valvular
heart disease requiring surgery were excluded. The diag-
nosis of HF was made by the attending physician based on
history, symptoms, physical signs and admission chest X-ray.
During the index hospitalization, two cardiologists speciﬁ-
cally recruited for this purpose reviewed all medical records
to validate the diagnosis of HF according to the Framingham
criteria amended by the European Society of Cardiology [5].
The diagnosis was not validated in 12 of the 811 patients
enrolled. Therefore, 799 patients (410 men and 389 women)
were ﬁnally included. Sixty-four (8%) patients died during
the index hospitalization and 735 (92%) were discharged
alive.
Clinical data, including medical history, cardiovascular
risk factors and results of complementary investigations
(laboratory tests, electrocardiogram, admission chest X-ray,
echocardiography and coronary angiography) were recorded
on individual case report forms.
Echocardiography was performed during the index hos-
pitalization in 648 patients, representing 81% of the study
population. Echocardiograms were performed according to
the guidelines of the American Society of Echocardiography
[6], were recorded on paper, stored in the patient’s ﬁle, and
analysed off-line. Results of echocardiograms performed
before the index hospitalization for HF were not available.
The cohort was divided in two groups: patients who under-
went an echocardiography during the index hospitalization
(Echo group) and patients in whom this investigation was not
performed (No-Echo group).
Medical treatment records were completed at admis-
sion and at discharge. Prescription of the main therapeutic
classes of drugs for HF (angiotensin-converting enzyme
[ACE]-inhibitors, beta-blockers, aldosterone antagonists,
diuretics, digoxin, oral anticoagulants, platelet aggregation
inhibitors, amiodarone, angiotensin receptor blockers and
nitrates) was recorded.
Prognosis
One-year and three-year overall mortality, and cardiovas-
cular mortality after admission, were determined. Sudden
death was classiﬁed as cardiovascular death. Vital status
was obtained either by consulting the general practitioner
or referring cardiologist or by referring to the civil reg-
istry. Cause of death was ascertained from hospital records,
death certiﬁcates and autopsy records or by contacting the
patients’ physician or referring cardiologist. No patients
were lost to follow-up.
Statistical analysis
Continuous variables are expressed as mean± standard
deviation and were compared using Student’s t-tests. Cate-
gorical variables are summarized by frequency percents and
were analysed using 2 tests.Univariate and multivariable analyses of overall and car-
diovascular mortality were made using Cox proportional
hazards models. The analysis of cardiovascular mortality
of the two groups (Echo and No-Echo) was performed in a
Cox multivariable model while patients who died of non-
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ardiovascular causes were censored (as non-events) at
he time of death. For multivariable analyses of mortal-
ty, we used a predeﬁned Cox multivariable model including
ovariates of potential prognostic importance: age, sex,
istory of hypertension, ischaemic aetiology, diabetes melli-
us, chronic obstructive pulmonary disease (COPD), cancer,
troke, estimated glomerular ﬁltration rate, natremia, car-
iomegaly, and hospitalization in cardiology departments.
eparate multivariable analyses were performed in patients
ischarged alive (n = 735), with adjustment for the above-
entioned covariates and medical therapy at discharge
ACE-inhibitors, beta-blockers, aldosterone antagonists,
ral anticoagulants, amiodarone, and nitrates). The assump-
ion of proportional hazards was checked using log-minus-log
urvival plots and by examining time-dependent covariates.
or continuous variables, the assumption of linearity was
ssessed by plotting residuals against independent variables.
ge, estimated glomerular ﬁltration rate and natremia were
ntered in the models as continuous variables. Adjusted
verall mortality curves for the two groups (Echo and No-
cho) were constructed after adjustment for the set of
ovariates in the multivariable model.
We further used Cox multivariable models to calculate
azard ratios (HR) with 95% conﬁdence intervals (CI) for
nalysis of the effect of echocardiography performance on
verall mortality by subgroups including age (cut-off 80
ears), sex, history of hypertension, coronary artery disease,
iabetes mellitus, COPD, renal insufﬁciency (cut-off for esti-
ated glomerular ﬁltration rate 60mL/min per 1.73m2) and
ardiomegaly. First-order interaction terms between perfor-
ance of echocardiography and the above covariates were
lso tested.
Data on survival of the two groups (Echo and No-Echo)
ere compared with the expected survival of persons of the
ame age and sex in the Somme department. Control data
ere obtained from French life tables of the Somme depart-
ent for 1999 provided by the French Institute of Statistics
INSEE) and represent the survival of the Somme general
opulation. The relative survival was computed as the ratio
f the observed to expected survival (observed number of
eaths/expected number of deaths in the general popula-
ion).
Since at admission patients were not randomly assigned
o have an echocardiography, selection biases were adjusted
or by developing a propensity score of echocardiography
erformance. We estimated the propensity scores (likeli-
ood of performing an echocardiography) at admission for
ach of the 799 patients by maximum likelihood regression
nalysis, using a multivariable logistic model, as described
reviously [7,8]. Baseline characteristics associated with
he performance of echocardiography on univariate anal-
sis (p≤ 0.2) were included in the multivariable model in
forward stepwise regression analysis. The goodness-of-ﬁt,
ssessed by the Hosmer-Lemeshow test (p = 0.58), and dis-
riminatory power of the model (area under the receiver
perating characteristic curve; C = 0.80) were good. Propen-
ity scores were then used to match each patient in the
o-Echo group to a unique patient from the Echo group
ith a propensity score within 2%. First, we matched each
atient in the No-Echo group with another patient in the
cho group that had the same ﬁve-digit propensity score
nd removed the matched patients from the database. The
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Table 1 Baseline characteristics according to the performance of echocardiography before and after matching.
Variable Prematch Postmatch
Echo (n = 648) No-Echo (n = 151) p Echo (n = 119) No-Echo (n = 119) p
Demographic data and medical history
Age (years) 73.9± 11.7 82.3± 10.0 < 0.001 80.3± 9.1 80.1± 9.9 0.87
Women 46.8% (303) 57.0% (86) 0.02 57.1% (68) 52.1% (62) 0.44
Hospitalization in cardiology departments 84.3% (546) 40.4% (61) < 0.001 53.8% (64) 51.3% (61) 0.70
Hospitalization in geriatric departments 4.8% (31) 35.8% (54) < 0.001 17.6% (21) 19.3% (23) 0.74
NYHA class III and IV on admission 95.1% (616) 96.7% (146) 0.39 98.3% (117) 96.6% (115) 0.41
Smoker 37.8% (245) 25.2% (38) 0.003 28.6% (34) 30.3% (36) 0.78
Signiﬁcant alcohol intake 8.3% (54) 5.3% (8) 0.21 5.9% (7) 6.7% (8) 0.79
History of hypertension 62.2% (403) 62.9% (95) 0.87 58.0% (69) 60.5% (72) 0.69
Ischaemic heart disease 36.4% (236) 43.7% (66) 0.09 48.7% (58) 45.4% (54) 0.60
History of myocardial infarction 12.8% (83) 12.6% (19) 0.94 20.2% (24) 15.1% (18) 0.31
Diabetes mellitus 25.6% (166) 19.9% (30) 0.14 19.3% (23) 22.7% (27) 0.52
Stroke 5.2% (34) 7.3% (11) 0.33 5.9% (7) 5.0% (6) 0.78
Chronic obstructive pulmonary disease 19.8% (128) 18.5% (28) 0.74 16.8% (20) 21.0% (25) 0.41
Cancer 10.6% (68) 11.3% (17) 0.78 13.4% (16) 11.0% (13) 0.57
ECG on admission
Atrial ﬁbrillation 33.6% (218) 30.5% (46) 0.46 38.7% (46) 31.9% (38) 0.28
Pathological Q wave 12.5% (81) 17.2% (26) 0.13 15.1% (18) 18.5% (22) 0.49
Left bundle branch block 13.4% (87) 14.6% (22) 0.71 13.4% (16) 16.8% (20) 0.47
Left ventricular hypertrophy 18.2% (118) 11.9% (18) 0.06 13.4% (16) 10.9% (13) 0.55
Chest X-ray data on admission
Cardiomegaly 73.1% (473) 57.6% (87) < 0.001 61.3% (73) 66.4% (79) 0.42
Pulmonary congestion 55.6% (360) 61.6% (93) 0.18 59.7% (71) 63.0% (75) 0.59
Laboratory data on admission
Sodium (mEq/L) 137.3± 4.6 137.2± 4.8 0.90 137.6± 4.5 137.2± 4.9 0.56
Potassium (mEq/L) 4.3± 0.7 4.2± 0.6 0.51 4.2± 0.6 4.3± 0.6 0.12
Creatinine clearance (mL/min per 1.73m2) 59.5± 24.0 54.2± 22.4 0.01 57.9± 22.0 55.7± 23.5 0.23
Baseline medical therapy
ACE inhibitors 16.8% (108) 15.2% (23) 0.65 12.7% (15) 16.0% (19) 0.48
Beta-blockers 17% (110) 12.6% (19) 0.18 10.9% (13) 15.1% (18) 0.34
Loop diuretics 24.4% (157) 27.2% (41) 0.48 22.9% (27) 26.1% (31) 0.52
Aldosterone antagonists 8.7% (56) 7.3% (11) 0.57 9.3% (11) 5.0% (6) 0.21
Digoxin 7.3% (47) 7.9% (12) 0.78 11.9% (14) 6.7% (8) 0.17
Nitrates 14.6% (94) 19.2% (29) 0.16 17.8% (21) 19.3% (23) 0.76
Angiotensin receptor blockers 5.4% (35) 2.0% (3) 0.07 3.4% (4) 1.7% (2) 0.40
Amiodarone 8.4% (54) 7.3% (11) 0.66 6.8% (8) 7.6% (9) 0.82
Oral anticoagulants 8.9% (57) 6.6% (10) 0.38 8.5% (10) 8.4% (10) 0.98
Platelet aggregation inhibitors 20.2% (130) 21.9% (33) 0.65 21.2% (25) 19.3% (23) 0.72
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presented in Fig. 3. The beneﬁcial effect of performance of
echocardiography was consistent across subgroups with the
exception of the group of HF patients without renal insufﬁ-
ciency (p for interaction 0.04). There was no interaction of
Figure 1. Adjusted three-year overall mortality curves forImpact of echocardiography in patients hospitalized for hea
procedure was repeated in the remaining patients with suc-
cessive matching by four-, three-, and two-digit scores. One
hundred and nineteen (78.8%) of the 151 patients in the No-
Echo group were successfully matched. The mean propensity
score in No-Echo patients before matching was 0.62039 com-
pared to 0.85284 in the Echo group (p < 0.001). In the group
that resulted after matching, the mean propensity score was
0.70764 in patients in whom echocardiography was not per-
formed, comparable to that of the Echo group (0.71716;
p = 0.985). The baseline characteristics of the groups that
resulted after matching were compared using Student’s
t-tests and 2 tests, as appropriate. After the matching pro-
cedure, no differences in baseline variables were observed
between the two groups (Table 1). Adjustment for covari-
ates of prognostic importance and confounding (propensity
score entered as a linear term) were performed in additional
Cox proportional analyses in the postmatch cohort.
For all tests, p≤ 0.05 was considered statistically signif-
icant. All p values resulted from two-sided tests. Statistical
analysis was performed with SPSS 13.0 (SPSS Inc., Chicago,
IL, USA).
The study complies with the Declaration of Helsinki and
was approved by local institutional review boards. Informed
consent was obtained from all patients. The database was
approved by the French computers and privacy commission.
Results
Baseline characteristics and treatment
Seven hundred and ninety-nine consecutive patients were
included. The mean age of the study population was 75± 12
years (sex ratio: 1.05). Echocardiography was not per-
formed during the index hospitalization in 151 patients
(19%: No-Echo group). Baseline characteristics of patients
according to the performance of an echocardiogram are
shown in Table 1. Patients in the No-Echo group were older
and comprised a larger proportion of women. The clinical
severity of HF on admission (New York Heart Association
[NYHA] functional class) and the frequency of hyperten-
sion, prior myocardial infarction and comorbidities such
as diabetes, stroke, COPD and cancer were not signiﬁ-
cantly different between patients in the Echo and No-Echo
groups. Patients in whom echocardiography was performed
had a signiﬁcantly lower rate of renal insufﬁciency, and
more often presented with cardiomegaly on the chest X-ray.
Echocardiography was performed in a signiﬁcantly higher
proportion of patients admitted to cardiology departments
versus those admitted to geriatric departments. Hospitaliza-
tion in departments other than cardiology (HR 7.1, 95% CI
4.5—11.2, p < 0.001), advanced (≥ 80 years) age (HR 2.4, 95%
CI 1.5—3.7, p < 0.001), and absence of cardiomegaly on chest
X-ray (HR 1.5, 95% CI 0.97—2.4, p = 0.06) were indepen-
dent parameters associated with the decision not to perform
echocardiography.
Valvular heart disease and idiopathic dilated cardiomy-
opathy were signiﬁcantly more frequent in the Echo group
(11.0% vs. 0.7%, p < 0.001 and 12.5% vs. 0.7%, p < 0.001,
respectively) whereas the frequencies of ischaemic aetiol-
ogy and hypertensive aetiology were comparable between
the Echo and No-Echo groups (p =NS). The cause of HF
p
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emained unidentiﬁed in 19.2% of patients in the No-Echo
roup compared to 2.5% in the Echo group (p < 0.001).
At discharge, patients in the No-Echo group received
igniﬁcantly lower prescription rates of ACE inhibitors, beta-
lockers, aldosterone receptor antagonists, anticoagulants
nd amiodarone (Table 2).
linical outcome
n the prematch population (n = 799), patients in the Echo
roup had a lower crude three-year overall mortality
ompared to those in the No-Echo group (HR 0.46, 95%
I 0.37—0.58, p < 0.001). On multivariable analysis, after
djustment for covariates, use of echocardiography was still
ssociated with a lower risk of overall death (HR 0.61, 95%
I 0.48—0.78, p < 0.001) (Table 3 and Fig. 1). The adjusted
isk of three-year cardiovascular mortality was signiﬁcantly
ower in patients in the Echo-group compared with the No-
cho group (HR 0.52, 95% CI 0.39—0.70, p < 0.001) (Table 3).
imilar results were obtained in patients surviving the index
ospitalization (Table 3).
The one-, two- and three-year survival rates were dra-
atically lower in the No-Echo group compared to the
xpected survival of the age- and sex-matched general pop-
lation (Fig. 2A); this difference was less impressive in the
cho group. The one-, two- and three-year relative survival
ates (i.e. ratio of observed to expected survival) of the Echo
roup were higher than those in the No-Echo group (Fig. 2B).
Associations between performance of echocardiography
nd overall mortality in subgroups of patients with HF areatients with heart failure in the Echo and No-Echo groups.
Adjusted for age, sex, history of hypertension, ischaemic aeti-
logy, diabetes mellitus, chronic obstructive pulmonary disease,
ancer, stroke, estimated glomerular ﬁltration rate, natremia, car-
iomegaly and hospitalization in cardiology departments.
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Table 2 Medical therapy in patients surviving the index hospitalization according to the performance of
echocardiography.
Variable Echo (n = 615) No-Echo (120) p
ACE inhibitors 58.6% (360) 33.9% (41) < 0.001
Beta-blockers 25.6% (157) 9.2% (11) < 0.001
Loop diuretics 89.1% (547) 90.1% (109) 0.75
Aldosterone antagonists 26.4% (162) 17.4% (21) 0.03
Digoxin 24.9% (153) 27.3% (33) 0.59
Nitrates 25.6% (157) 40.5% (49) 0.001
Angiotensin receptor blockers 3.9% (24) 2.5% (3) 0.45
Amiodarone 34.9% (214) 24.0% (29) 0.02
Oral anticoagulants 30.9% (190) 19.8% (24) 0.01
Platelet aggregation inhibitors 37.5% (230) 31.4% (38) 0.21
Table 3 Impact of echocardiography on three-year outcome: results of Cox univariate and multivariable analyses.
Overall mortality Cardiovascular mortality
n/events HR 95% CI p n/events HR 95% CI p
Overall population on admission 799/381 799/244
Univariate 0.46 0.37—0.58 < 0.001
Adjusteda 0.61 0.48—0.78 < 0.001 0.52 0.39—0.70 < 0.001
Patients alive at discharge 735/317 735/187
Univariate 0.54 0.42—0.71 < 0.001
Adjustedb 0.73 0.55—0.98 0.03 0.63 0.44—0.92 0.016
a Adjusted for: age, sex, history of hypertension, ischaemic aetiology, diabetes mellitus, chronic obstructive pulmonary disease, cancer,
stroke, estimated glomerular ﬁltration rate, natremia, cardiomegaly, and hospitalization in cardiology departments.
b Adjusted for all covariates in model 1 and treatment on discharge (ACE inhibitors, beta-blockers, aldosterone antagonists, oral
p
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panticoagulants, amiodarone, and nitrates).
erformance of echocardiography with age (p = 0.26) or sex
p = 0.14).In propensity-matched patients (n = 238), the perfor-
ance of echocardiography during hospitalization was
ssociated with a signiﬁcant 42% reduction in the relative
isk of three-year crude overall mortality (HR 0.58, 95% CI
c
p
m
(
igure 2. A: observed survival of the Echo and No-Echo groups durin
ge- and sex-matched general population. B: relative survival for patien
ercentage of the expected survival..41—0.81, p = 0.001). After adjustment for covariates of
rognostic importance and for propensity scores, the asso-
iation remained signiﬁcant (HR 0.55, 95% CI 0.39—0.79,
= 0.001). The risk of three-year cardiovascular mortality in
atched patients was signiﬁcantly lower for the Echo group
HR 0.59, 95% CI 0.37—0.95, p = 0.03).
g follow-up (12, 24 and 36 months) and expected survival of an
ts in the Echo and No-Echo groups during follow-up expressed as a
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oFigure 3. Impact of echocardiography on three-year overall mort
Discussion
This study shows that approximately 20% of patients hos-
pitalized for a ﬁrst episode of HF did not have an
echocardiography during hospitalization. Patients in whom
echocardiography was not performed received lower dis-
charge prescription rates of ACE inhibitors, aldosterone
receptor antagonists, beta-blockers, anticoagulants and
amiodarone. Using propensity scores and multivariable
analysis to reduce the signiﬁcant imbalance in baseline
characteristics between the Echo and No-Echo groups, we
demonstrate that echocardiography was associated with
a better clinical outcome. Thus, the three-year relative
risk of overall and cardiovascular mortality of the No-
Echo group was signiﬁcantly higher than that of the Echo
group. Moreover, a dramatic excess mortality compared to
the expected survival of the age- and sex-matched gen-
eral population was observed in patients in the No-Echo
group.
Echocardiography is the investigation of choice to assess
cardiac dysfunction [1,2]. It is a cost-effective procedure
that provides major prognostic data in patients with HF,
including ejection fraction, left ventricular size, ﬁlling pres-
sures, pulmonary pressures and, more recently, longitudinal
contraction [9]. Recent data document the role of echocar-
diography in predicting age-related cardiovascular events in
the general population, with a major impact on primary pre-
vention strategies [10]. The technique is increasingly used
to identify patients with structural heart disease, who are
at risk of developing symptomatic HF [11], and to assess
response to therapy.
i
s
e
l
vin patient subgroups with heart failure.
In recent cohort studies conducted in patients with HF,
chocardiography was performed in 42 to 85% of cases
12—15]. In our study, echocardiography was performed dur-
ng the index hospitalization in 81% of patients admitted for
ﬁrst episode of HF.
Patients in the No-Echo group were older and more
requently women. Renal insufﬁciency was more frequent
mong patients in the No-Echo group, probably as a con-
equence of their advanced age. Absence of cardiomegaly
n the chest X-ray was related to the decision not to
erform echocardiography, reﬂecting the fact that some
on-cardiologists may still consider HF with preserved ejec-
ion fraction in elderly patients a less severe condition
han systolic HF. However, recent reports demonstrate that
hese two conditions have comparable long-term progno-
is [12,13]. Advanced age was an important parameter
ssociated with the decision not to perform echocardio-
raphy in patients hospitalized in geriatric departments
nd therefore managed largely by non-cardiologists. Recent
tudies have suggested that patients with HF treated
y cardiologists differ signiﬁcantly from those managed
y internists, general practitioners and other physicians
16—18], and that care by a cardiologist is associated with
reduced hazard for death and hospital readmission for
F in both hospitalized patients and outpatients with new-
nset HF [16,19]. In all healthcare institutions participating
n the present study, patients were grouped according to
ervice (cardiology, internal medicine or geriatrics). How-
ver, as echocardiography facilities were institution based,
ower ordering rates of echocardiograms in certain ser-
ices (e.g. geriatrics) suggest a less intensive diagnostic
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nd therapeutic approach in patients managed by non-
ardiologists.
In our study, patients in the No-Echo group received
ess aggressive therapy for HF and lower discharge pre-
cription rates of life-saving drugs. This may be in part
consequence of the advanced age, high prevalence of
enal insufﬁciency, and inherent difﬁculties in managing HF
n elderly patients. It has also been reported that beta-
lockers and ACE inhibitors are more frequently prescribed
n patients treated by cardiologists [16,17,19]. Patients
n whom echocardiography was performed probably had a
ore accurate diagnosis and therefore a better guideline-
ased therapy.
Very few data are available on the prognostic impact
f echocardiography in patients with HF. In a community-
ased retrospective study involving 216 patients reported
y Senni et al., crude survival was not signiﬁcantly differ-
nt between patients investigated by echocardiography and
hose in whom this examination was not performed [4]. How-
ver, after adjustment for age, sex and NYHA class, patients
hat did not undergo echocardiography had a poorer out-
ome. In our study, both crude and adjusted overall survival
ates were lower in patients in the No-Echo group. The sig-
iﬁcantly higher mortality of the No-Echo group compared
ith that of the general population supports these ﬁndings.
Subgroup analyses revealed a striking mortality beneﬁt of
chocardiography in various categories of patients with HF.
nterestingly, the performance of echocardiography was not
ssociated with improved outcome in HF patients without
enal insufﬁciency. It is widely acknowledged that patients
ith renal disease are at high risk for developing cardio-
ascular diseases, including HF. Impaired renal function is
ssociated with higher death rates and more frequent hos-
italizations in patients with chronic HF [20]. Assessment of
ardiac function with echocardiography appears to be asso-
iated with greater survival beneﬁt in high-risk patients with
ew-onset HF.
After the propensity-matching procedure, the perfor-
ance of echocardiography remained associated with a
igniﬁcant reduction in the relative risk of three-year overall
ortality. This result is important and supports our assump-
ion that the lack of recognition of underlying heart diseases
n the No-Echo group was the main factor precluding
hese patients from receiving appropriate therapy. Matched
atients had comparable baseline variables including comor-
idities, suggesting that these conditions apparently did not
nﬂuence the therapeutic decision. Improved management
f this elderly HF population by widespread use of echocar-
iography may have a favorable impact on survival and on
rescription of appropriate therapy before discharge. The
nitiation of HF therapy before discharge results in improved
ompliance and better long-term clinical outcomes [21].
Our study was exclusively hospital based with the advan-
age of prospectively recruiting all potential individuals
ho met the inclusion criteria. The main limitation of our
tudy is that the performance of echocardiography was non-
andomized. However, a randomized trial comparing Echo
ersus non-Echo strategies has never been performed and
eems ethically unacceptable. We acknowledge that sub-
roup analyses may be inﬂuenced by the small size of the
amples and insufﬁcient power to test for interactions [22].
n our cohort, although not systematically performed dur-C. Tribouilloy et al.
ng the ﬁrst hours after the patient’s admission to hospital,
chocardiography was available for the clinical decision-
aking. However, our data cannot exclude the confounding
f intentional selection bias based on the patient’s clinical
tatus beyond the documented variables. Moreover, fail-
re to order echocardiography may represent a marker of
passive management strategy. In our series, echocardio-
rams were not recorded on videotape. We acknowledge
hat off-line analysis of echocardiograms recorded on paper
ay be incomplete and that some abnormalities can be
issed.
onclusions
chocardiography it still underused in patients admitted for
ﬁrst episode of HF, especially in elderly patients managed
y non-cardiologists. The use of echocardiography is associ-
ted with better quality of care and outcomes for in-patients
ith HF. Systematic use of echocardiography in all patients
ospitalized for HF could improve diagnosis and prescription
ates of life-saving drugs and substantially reduce the risk
f future hospitalizations and death.
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